For the quarter ended December 2025, Ecolab (ECL) reported revenue of $4.2 billion, up 4.8% over the same period last year. EPS came in at $2.08, compared to $1.81 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $4.19 billion, representing a surprise of +0.07%. The company delivered an EPS surprise of +0.8%, with the consensus EPS estimate being $2.06.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Ecolab performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:- Net Sales- Fixed Currency Rates- Global Pest Elimination: $307.2 million versus the three-analyst average estimate of $308.05 million. The reported number represents a year-over-year change of +4.1%.
- Net Sales- Fixed Currency Rates- Global Water: $2.02 billion versus $2.02 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -2.4% change.
- Net Sales- Fixed Currency Rates- Global Life Sciences: $191.4 million versus $186.29 million estimated by three analysts on average.
- Net Sales- Fixed Currency Rates- Global Institutional & Specialty: $1.5 billion compared to the $1.52 billion average estimate based on three analysts. The reported number represents a change of +9.6% year over year.
- Net Sales- Public Currency Rates- Global Life Sciences: $207.3 million versus the two-analyst average estimate of $197.5 million.
- Net Sales- Public Currency Rates- Global Pest Elimination: $316.5 million compared to the $320.4 million average estimate based on two analysts. The reported number represents a change of +7.7% year over year.
- Net Sales- Public Currency Rates- Global Institutional & Specialty: $1.55 billion versus $1.54 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +14% change.
- Net Sales- Public Currency Rates- Global Water: $2.12 billion compared to the $2.15 billion average estimate based on two analysts. The reported number represents a change of +4.4% year over year.
- Operating Income (loss)- Fixed Currency Rates- Global Life Sciences: $32.6 million versus the three-analyst average estimate of $32.86 million.
- Operating Income (loss)- Fixed Currency Rates- Global Pest Elimination: $62.4 million versus the three-analyst average estimate of $62.72 million.
- Operating Income (loss)- Fixed Currency Rates- Global Institutional & Specialty: $334.8 million compared to the $337.21 million average estimate based on three analysts.
- Operating Income (loss)- Fixed Currency Rates- Corporate: $-122 million compared to the $-48.09 million average estimate based on three analysts.
View all Key Company Metrics for Ecolab here>>>
Shares of Ecolab have returned +6.3% over the past month versus the Zacks S&P 500 composite's no change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Just Released: Zacks Top 10 Stocks for 2026
Hurry – you can still get in early on our 10 top tickers for 2026. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful.
From inception in 2012 through November, 2025, the Zacks Top 10 Stocks gained +2,530.8%, more than QUADRUPLING the S&P 500’s +570.3%.
Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2026. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>Ecolab Inc. (ECL) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
